Usefulness of Red Cells Distribution Width to Predict Worse Outcomes in Patients With Atrial Fibrillation
Section snippets
Methods
From February 1st 2016 to August 31st 2017, we prospectively enrolled AF patients in 2 observational registries. The 2 registries, the first one promoted by the European Society of Cardiology (ESC)15 and the second being a spontaneous, nonfunded one, had similar design, being differentiated only by the time course, and were approved by the local ethics committee, and all the patients provided written informed consent. All patients were enrolled consecutively, with no overlap between the 2
Results
A total of 457 patients were enrolled with 176 (38.5%) being inpatients from the cardiology ward.
AF patients were categorized according to the RDW tertiles, as follows: (1) 171 (37.4%) in the lowest tertile; (2) 141 (30.9%) in the intermediate tertile; (3) 145 (31.7%) in the highest tertile. Clinical characteristics of patients according to RDW tertiles were reported in Table 1. Patients were progressively older in relation to increasing tertiles. No difference was found in terms of oral
Discussion
In this study, derived from a contemporary, real-world cohort of AF patients, we found that several clinical factors indicating a worse clinical profile are associated with higher RDW values. Second, a significant association between baseline RDW values and a worse profile in terms of CHA2DS2-VASc and HAS-BLED scores was found. Third, higher RDW values were associated with an increased rate of all-cause death and of the composite end point of clinically relevant events. In literature the
Disclosures
VLM reports small speaker's fee for Bayer, Boehringer, Daiichi Sankyo, Mylan; MP reports consulting activity for Boehringer Ingelheim; GYHL has served as consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon, and Daiichi-Sankyo, and as speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo; GB has received small speaker's fee from Medtronic, Boston, Boehringer, and Bayer, outside of the submitted work. The other authors declare
References (30)
- et al.
Red cell distribution width as a novel, inexpensive marker for paroxysmal atrial fibrillation
Int J Cardiol
(2014) - et al.
The relationship between elevated red cell distribution width and long-term outcomes among patients with atrial fibrillation
Clin Biochem
(2015) - et al.
Red cell distribution width and all-cause mortality in patients with atrial fibrillation: a cohort study
J Arrhythm
(2017) - et al.
Association between red cell distribution width and risk of venous thromboembolism
Thromb Res
(2015) - et al.
Red cell distribution width and risk for venous thromboembolism: a population-based cohort study
Thromb Res
(2014) - et al.
Red cell distribution width as a bleeding predictor after percutaneous coronary intervention
Am Heart J
(2013) - et al.
Association between red cell distribution width and thromboembolic events in patients with atrial fibrillation
Eur J Intern Med
(2017) - et al.
The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review)
Vascul Pharmacol
(2015) - et al.
Red blood cell distribution width: a simple parameter with multiple clinical applications
Crit Rev Clin Lab Sci
(2015) - et al.
Red cell distribution width and common disease onsets in 240,477 healthy volunteers followed for up to 9 years
PLoS One
(2018)
Red blood cell distribution width and the risk of death in middle-aged and older adults
Arch Intern Med
Red blood cell distribution width and cardiovascular diseases
J Thorac Dis
Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes
Clin Chem Lab Med
The role of red blood cell distribution width in cardiovascular and thrombotic disorders
Clin Chem Lab Med
Red blood cell distribution width in heart failure: a narrative review
World J Cardiol
Cited by (15)
Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry
2022, European Journal of Internal MedicineCitation Excerpt :However, with the advent of high-sensitivity (hs)-cTn assays, elevated levels of cTn may be a common finding in daily clinical practice even in several non-ischaemic, acute or chronic conditions, such as heart failure (HF), chronic kidney disease (CKD), sepsis, inflammatory diseases, etc. [4–10]. In the last decades, several biomarkers have emerged as significant predictors for adverse outcomes in atrial fibrillation (AF) patients [11–14]. As for the other clinical conditions reported above, independent of the specific assay used, cTn elevations may be detected in AF patients with or without overt coronary artery disease (CAD) [15,16].
Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology
2021, European Journal of Internal MedicineCitation Excerpt :More complicated stroke risk scores other than CHA2DS2VASc have been proposed, including more and more clinical risk factors, but this leads to a reduction in simplicity and practical application in busy everyday clinical settings. The addition of biomarkers, such as clotting markers (e.g. von Willebrand factor, troponin, natriuretic peptides, etc.) will always improve on risk prediction, at least statistically – but in real world cohorts, their performance has been disappointing with limited added value over conventional clinical risk scores [51-53]. Also, biomarkers are likely to reflect a sick patient (or a sick heart) and are non-specific for the outcome of interest, ischaemic stroke.
Atrial fibrillation in pneumonia: what clinical implications at long-term?
2023, Internal and Emergency MedicineNew Perspectives on Risk Stratification and Treatment in Patients with Atrial Fibrillation: An Analysis of Recent Contributions on the Journal of Cardiovascular Disease and Development
2023, Journal of Cardiovascular Development and DiseaseNomogram for Predicting Postoperative Portal Venous Systemic Thrombosis in Patients with Cirrhosis Undergoing Splenectomy and Esophagogastric Devascularization
2022, Canadian Journal of Gastroenterology and Hepatology
Vincenzo Livio Malavasi, Marco Proietti, and Giuseppe Boriani take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
All other authors contributed significantly to the paper with data collection and paper revision for important intellectual content. All authors read and approved the final version of the manuscript.
Funding: No funding was received for this work.
- 1
Joint first authors.
- 2
Joint senior authors.